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We recently reported that the ruptured regions of the human anterior cruciate ligament (ACL) contained vas-
cular-derived stem cells, which showed the potential for high expansion and multilineage differentiation. In 
this study, we performed experiments to test the hypothesis that ACL-derived CD34+ cells could  contribute to 
tendon–bone healing. ACL-derived cells were isolated from the rupture site of human ACL by fluorescence-
activated cell sorting. Following ACL reconstruction, immunodeficient rats received intracapsular administra-
tion of either ACL-derived CD34+ cells, nonsorted (NS) cells, CD34- cells, or phosphate-buffered saline (PBS). 
We also performed in vitro cell proliferation assays and enzyme-linked immunosorbent assays for vascular 
endothelial growth factor (VEGF) secretion. We confirmed the recruitment of the transplanted cells into the 
perigraft site after intracapuslar injection by immunohistochemical staining at week 1. Histological evaluation 
showed a greater area of collagen fiber formation and more collagen type II expression in the CD34+ group than 
the other groups at the week 2 time point. Immunostaining with isolectin B4 and rat osteocalcin demonstrated 
enhanced angiogenesis and osteogenesis in the CD34+ group at week 2. Moreover, double immunohistochemi-
cal staining for human-specific endothelial cell (EC) and osteoblast (OB) markers at week 2 demonstrated 
a greater ability of differentiation into ECs and OBs in the CD34+ group. Microcomputerized tomography 
showed the greatest healing of perigraft bone at week 4 in the CD34+ cell group, and the failure load of tensile 
test at week 8 demonstrated the greatest biomechanical strength in the CD34+ group. Furthermore, the in vitro 
studies indicated that the CD34+ group was superior to the other groups in their cell proliferation and VEGF 
secretion capacities. We demonstrated that ACL-derived CD34+ cells contributed to the tendon–bone healing 
after ACL reconstruction via the enhancement of angiogenesis and osteogenesis, which also contributed to an 
increase in biomechanical strength.
Key words: Anterior cruciate ligament; Stem cells; Reconstruction; Tendon–bone healing; Angiogenesis; 
Osteogenesis
INTRODUCTION
Anterior cruciate ligament (ACL) rupture is one 
of the most common knee injuries in sports medicine. 
Approximately 100,000 ACL reconstructions are per-
formed annually in the United States alone (12). In most 
cases, spontaneous ACL healing fails to take place and 
reconstruction of the ACL is required, which has become a 
routine surgical procedure under arthroscopic observation. 
Whereas most surgical procedures for ACL reconstruction 
require the tendon grafts to heal in a surgically created bone 
tunnel, the attachment between the tendon and the bone is 
the weakest region in the early posttransplantation period 
(3–5,10). Indeed, it has been reported that the mechanical 
properties of the healing ligament do not return to normal 
1 year after ACL reconstruction surgery in both rabbit and 
canine models (37,39). Furthermore, Delay et al. reported 
a human case of ACL reconstruction in which the core 
portion of the patellar tendon graft remained necrotic 18 
months after surgery (9). The lack of vascularity within 
the ACL graft may induce degeneration or microruptures 
of the grafted tendon during the postoperative period (36). 
Therefore, in this surgery using tendon grafts, the tendon 
graft’s ability to heal to the bone is one of the important 
key factors for successful reconstruction and an early 
return to normal activity. Some recent articles have shown 
that the enhancement of angiogenesis, using cytokines 
or growth factors, led to prompt tendon–bone healing 
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(15,31,41). On the other hand, stem/progenitor cells, such 
as endothelial progenitor/CD34+ cells, have also been used 
and shown to promote neovascularization in the ischemic 
area (6,16,18,19), and these stem cells have been generally 
considered to be a promising cell source for tissue regen-
eration treatments because of their potential for high levels 
of expansion, self-renewal, and multipotent differentiation 
capacities. Recently, blood vessels have been reported to 
possess a rich supply of stem/progenitor that express the 
cell surface markers CD34 (8,14,35,42). Our laboratory 
has also identified and purified, via flow cytometry, the 
cell population that are developmentally and anatomi-
cally related to the blood vessel walls in human tissues. 
This population of cells can be found in the skeletal mus-
cle, including myoendothelial cells that coexpress mark-
ers of endothelial and myogenic cells (CD34 and CD56). 
Also, this population exhibits multilineage developmental 
potentials, in culture and in vivo, and has been shown to 
differentiate into skeletal myofibers, bone, cartilage, and 
adipocytes (7,8,42). Moreover, we recently reported that 
the ruptured and septum regions of the human ACL con-
tained numerous vascular-derived stem cells and that ACL-
derived CD34+ cells showed potentials for high expansion 
and multilineage differentiation capacities (26). Based on 
these latter findings, we performed experiments to test the 
hypothesis that the transplantation of human ACL-derived 
CD34+ cells derived from the site of ACL rupture could 
contribute to tendon–bone healing and regeneration. 
MATERIALS AND METHODS
Samples 
Human adult ACL-ruptured tissues were harvested 
from subjects undergoing arthroscopic primary ACL 
reconstruction after informed consents by all patients 
(22.5 ± 3.8 years old, 5.1 ± 1.9 months postinjury, n = 8). 
The rupture sites of all samples were at the femoral attach-
ment sites. The IRB protocols were approved by the insti-
tutional review board at the University of Pittsburgh.
Cell Isolation 
The human adult ACL tissues were transported in ster-
ile saline solution on ice. The excised ACL tissues were 
dissected into two regions, the rupture site and the mid-
substance site. The tissues were minced into small pieces 
approximately 1–2 mm3, washed three times in phosphate-
buffered saline (PBS) (Sigma Aldrich, St. Louis, MO), and 
were then digested with 0.4% collagenase type I (0.4% 
w/v) (Invitrogen, Carlsbad, CA) in Dulbecco’s modified 
Eagle’s medium (DMEM) (Sigma) supplemented with 10% 
fetal bovine serum (FBS) (Invitrogen) and 1% penicillin/ 
streptomycin (standard medium) (Invitrogen) for 4–6 h. 
Cells were spun down, resuspended in medium, passed 
through a 70-μm pore size nylon filter (BD, Bedford, MA), 
and washed twice with the same type of medium. Isolated 
cells from each region were cultured for 2–3 days in the 
standard DMEM medium.
These cells were first incubated with mouse serum 
(Sigma; 1:10) in fluorescence-activated cell sorter (FACS) 
buffer (BD Pharmingen, Bedford, MA) for 10 min on 
ice and were then incubated with CD34-allophycocyanin 
(APC; BD Pharmingen) for 30 min. To exclude dead cells, 
7-aminoactinomycin D (Via-probes, BD Pharmingen) was 
added to each tube. Live cells were analyzed using a FACS 
Aria Cell-Sorting System (BD) and Cell Quest software 
(BD). After examining the cell marker profiles, the cells 
were gated out and CD34+ and CD34- cells were sorted 
following a protocol described by Zheng et al. (42) and 
Crisan et al. (8), as shown in our previous study (26). 
Animal Model of ACL Reconstruction
A reproducible model of ACL reconstruction was cre-
ated in immunodeficient rats with autologous flexor digito-
rum longus tendon as a graft according to a previous report 
(20). The animal experiments conducted as a part of this 
study were approved by the Institutional Animal Care and 
Use Committee in University of Pittsburgh. Forty 10-week-
old female nude rats (NIH-Whn NIHRNU-M; Taconic, 
Germantown, NY) were used for these experiments. The 
animals were anesthetized with 3% isoflurane and O2 gas 
(1.5 L/min) delivered through an inhalation mask. A longi-
tudinal incision was made on the medial aspect of the distal 
leg and ankle, and the flexor digitorum longus tendon was 
identified and then cut just distal to the ankle. The full length 
of the flexor digitorum longus tendon (average length, 
20 mm) was harvested. A second incision was made over 
the knee, a lateral parapatellar arthrotomy was performed, 
and the native ACL was excised. Using an 18-gauge nee-
dle, a bone tunnel was made in the proximal tibia and the 
distal femur, entering the joint at the attachment sites of the 
ACL. A 4-0 Ethibond suture (Ethicon, Somerville, NJ) was 
passed through each end of the previously harvested ten-
don graft, and then the graft was passed through the bone 
tunnels to replace the ACL. Both ends of the grafted tendon 
were secured to the surrounding periosteum at the extra-
articular tunnel exit site at the distal femur and proximal 
tibia using 4-0 Ethibond suture. The wounds were closed 
in routine fashion. It took approximately 10 min to perform 
the ACL reconstruction surgical procedure, and then the 
animals were allowed ad lib activity postoperatively.
Cell Transplantation
Three days after ACL reconstruction, the rats received 
a 50-ml intracapsular injection of one to the following: 
(1) ACL-derived CD34+ cell: 5 ´  105 cells (CD34+ group) 
in PBS, (2) ACL-derived nonsorted (NS) cell: 5 ´  105 
cells (NS group) in PBS, (3) ACL-derived CD34- cell: 
5 ´  105 cells (CD34- group) in PBS, or (4) no cells (PBS 
only) (PBS group).
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Tissue Harvest
Rats were euthanized by CO2 overdose. The femur–
graft–tibia complexes were harvested and quickly 
embedded in optimal cutting temperature (OCT) com-
pound (Miles Scientific, Elkhardt, IN), snap frozen in liq-
uid nitrogen, and stored at -80°C for histochemical and 
immunohistochemical staining as described below. 
Histological Examination 
The embedded femur–graft–tibia complexes were sec-
tioned at 6 μm, and the serial sections were mounted on 
silane-coated glass slides (Sigma) and air dried for 1 h 
before being fixed with 4% paraformaldehyde at 4°C for 5 
min and then stained immediately. Hematoxylin and eosin 
(H&E) staining was performed to identify the interface zone 
between the grafted tendons and bone following standard 
protocols. Also, tissue sections were stained with Masson’s 
trichrome elastin to identify collagen fibers at week 2 (n = 6 
in each group) according to standard operating procedures.
Quantification of Collagen Fibers
The areas of the entire visible tendon–bone interface and 
collagen fibers within the interface were measured, respec-
tively, in histological sections stained with Masson trichrome 
by Scion Image analysis software (Scion Corporation, 
Frederick, MD), which is based on the popular NIH image 
J software originally designed for the Macintosh platform. 
The collagen fiber area was divided by the tendon–bone 
interface area to obtain the proportion of the collagen fibers 
to the entire tendon–bone interface. Three sections were 
examined per specimen, and the quantification of collagen 
fibers was analyzed by three blinded examiners who were 
not informed of the group assignment.
Immunofluorescence Staining to Detect Chondrocytes  
at the Interface Zone
To detect chondrocytes at the interface zone between 
the bone-ligament junction, immunofluorescent staining 
for type II collagen (Col2) was performed at the 2 week 
time point using rabbit anti-rat Col2 antibody (Sigma) 
to detect chondrocytes and Alexa Fluor 594-conjugated 
donkey anti-rabbit IgG (Molecular Probes, Eugene, OR) 
at a 1:200 dilution as a secondary antibody. The numbers 
of Col2-positive cells were morphometrically counted in 
five randomly selected soft tissue fields using Northern 
Eclipse software (Empix Imaging, Inc., Cheektowaga, 
NY), and the averages were determined.
Immunofluorescent Staining to Detect Transplanted 
Cells 
To trace transplanted human cells in the rat knee joint, 
immunohistochemistry (n = 4, in each group) was performed 
at week 1 with a mouse anti-human nuclear antigen (HNA) 
antibody (Millipore Corporate Headquarters, Billerica, 
MA). This anti-HNA antibody was used at 1:100 dilution 
and incubated at room temperature for 1 h. The secondary 
antibody used against HNA was Alexa Fluor 594-conju-
gated goat anti-mouse IgG (Molecular Probes) used at 1:200 
dilution and incubated at room temperature for 2 h. 4,6- 
Diamidino-2-phenylindole (DAPI) solution was applied for 
5 min for nuclear counterstaining. After staining, we evalu-
ated the number of double stained cells in five randomly 
selected fields (250 ´  250 μm) of the tissue at the interface 
zone between the bone and tendon using Northern Eclipse 
software (Empix Imaging, Inc., Cheektowaga, NY).
Human Cell-Derived Vasculogenesis and Osteogenesis
To detect transplanted human cells at the interface zone 
between bone and tendon in the rats, double immunohis-
tochemistry (n = 6, in each group) was performed at week 
2 using a human-specific CD31 (hCD31) antibody (Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA), a human-specific 
osteocalcin (hOC) antibody (Abcam, Cambridge, MA), and 
the HNA antibody to detect human cells and murine-specific 
endothelial cell (EC) marker isolectin B4-fluorescein iso-
thiocyanate (FITC)-conjugated antibody (Vector Laboratories, 
Burlingame, CA) to detect mouse ECs (18). The primary 
antibodies for immunostaining were: hCD31, hOC anti-
gen, HNA, or isolectin B4-FITC conjugate and used at a 
1:100 dilution and incubated at room temperature for 1 h. 
The following fluorophore conjugated secondary antibod-
ies were used against the primary antibodies: Alexa Fluor 
594-conjugated goat anti-mouse IgG (Molecular Probes) 
was used at 1:200 dilution at room temperature for 2 h to 
detect hCD31 and HNA; Alexa Fluor 488-conjugated goat 
anti-mouse IgG (Molecular Probes) was used at 1:200 dilu-
tion at room temperature for 2 h to detect hOC. DAPI solu-
tion was applied for 5 min for nuclear counterstaining. After 
staining, we evaluated the number of double-stained cells in 
five randomly selected fields (250 ´  250 μm) of the tissue 
at the interface zone between the bone and tendon using 
Northern Eclipse software (Empix Imaging, Inc.).
Morphometric Evaluation of Capillary Density and 
Osteoblast Density
Using immunohistochemical staining for murine-spe-
cific EC marker isolectin B4-FITC conjugate (Vector), a rat- 
specific endothelial marker, the regenerated capillaries, and/
or neovascularity could be visualized and quantified using 
fluoromicroscopy at week 2 posttreatment (n = 6 in each 
group). Regenerated bone and/or newly formed bone were 
visualized and recognized using an antibody against the rat 
OC antigen (Santa Cruz), which identified rat osteoblasts 
(OB) at week 2 posttreatment (n = 6 in each group). The 
murine-specific EC marker isolectin B4-FITC conjugate and 
rat OC antigen were used as the primary antibodies at 1:100 
dilution and incubated at room temperature for 1 h. The sec-
ondary antibody against the rat OC antibody was Alexa Fluor 
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488-conjugated donkey anti-goat IgG (Molecular Probes) 
used at a 1:200 dilution and incubated at room temperature 
for 2 h. After staining, we also evaluated the capillary and 
OB densities by analyzing five randomly selected fields 
(250 ´  250 μm) of the tissue at the interface zone between 
bone and tendon using Northern Eclipse software. 
RNA Isolation and Reverse Transcriptase Polymerase 
Chain Reaction Analysis 
Total RNA was extracted from cells or pellets using 
RNeasy plus Mini Kit (Qiagen) in accordance with the man-
ufacturer’s instructions. One microgram of total RNA was 
used for random hexamer-primed cDNA synthesis using 
reverse transcription of the SuperScript II preamplification 
system (Invitrogen). Equal amounts of cDNA synthesis were 
used as templates for RT-PCR amplification per 25 μl reac-
tion volume using Taq DNA polymerase (Invitrogen) and 
50 pmol of gene-specific primers. The sequences and product 
sizes of the primers for VE-cadherin (VE-cad), CD31, type 
I collagen (COL I), osteocalcin (OC), and b-actin are listed 
below. RT-PCR amplifications were performed by preheat-
ing the mixture at 95°C for 5 min followed by 35 cycles of 
1 min at 95°C, 45 s at 58°C, and 1 min at 72°C. A final 
extension of 10 min was performed at 72°C. The PCR prod-
ucts were resolved by electrophoresis on 1.5% agarose gels 
and visualized by ethidium bromide staining. The mRNA 
expression of b-actin was used to normalize gene expres-
sion. Total RNA extracted from fetal bone and human 
umbilical vein endothelial cells (HUVECs) were used as 
positive controls for osteogenic and endotheliogenic gene 
expression. Primers used were hVE-cad (461 bp): sense 
ACGCCTCTGTCATGTACCAAATCCT and antisense 
GGCCTCGACGATGAAGCTGTATT; hCD31 (469 bp) 
(28): sense: AAGTCAAGCAGCATCGTGGTCAACAT 
and antisense TTGTCTTTGAATACCGCAG; hCOL1 
(600 bp): sense TGACGAGACCAAGAACTG and anti-
sense CCATCCAAACCACTGAAACC; hOC (300 bp): 
sense GTGCAGAGTCCAGCAAAGGT and antisense 
GCAAGGGGAAGAGGAAAGAA; hb-actin (205 bp): 
sense CCTCGCCTTTGCCGATCC and antisense GGA 
ATCCTTCTGACCCATGC.
Micro-CT Evaluation
The perigraft bone volume was evaluated using a 
high-resolution micro-CT (μCT-40, Scanco Medical, 
Brüttisellen, Switzerland) (n = 6 in each group). The 
rats were anesthetized with 3% isoflurane and O2 gas 
(1.5 L/min) delivered through an inhalation mask and 
placed with their long axes in the vertical position and 
immobilized with a foam pad in a cylindrical sample 
holder. The continuous scans were performed perpen-
dicular to the long axis of the limb at an isotropic reso-
lution of 30 μm3. A region of interest (ROI) of 6 mm 
in diameter was user-defined to cover the bone tunnel 
and the 1 mm of the tibial tunnel from the proximal 
end was analyzed. The same ROI was used on all of 
the samples acquired postoperatively from weeks 0, 2, 
and 4. The acquired 3D data set was convoluted with 
a 3D Gaussian filter with a width and support equal to 
1.2 and 2, respectively. Bone was segmented from the 
marrow and soft tissue for subsequent analyses using a 
global thresholding procedure. A threshold equal to or 
above 210 represented bone tissue; a threshold below 
210 represented bone marrow and soft tissue. The bone 
volume/tissue volume (BV/TV) was evaluated using 
the built-in software of micro-CT.
Biomechanical Assessment
Eight weeks after surgery, four knees from each group 
were biomechanically tested. As a control group, four 
uninjured rat knees were also prepared for biomechani-
cal testing. Before the biomechanical tests, the hind limbs 
were completely freed of all soft tissue except for the ACL 
graft, which was carefully dissected. The femur and tibia 
were cut 20 mm from the joint line, and both femur and 
tibia were fixed in a cylinder hole of the specially designed 
aluminum plate using super glue. The prepared femur–
ACL–tibia complex was mounted in a conventional tensile 
tester, DS2 (Imada, Inc, Northbrook, IL), and an applied 
load was directed along the longitudinal axis of the ACL 
graft. Before testing, we applied 10 cycles of longitudinal 
loads of 1 N to the knee specimen as a preconditioning. 
After preconditioning, each femur–ACL–tibia complex 
was stretched at a crosshead speed of 0.25 mm/s until 
gross failure of the ACL occurred. In addition to the ten-
sile tests on the operated knees, biomechanical tests were 
also performed on healthy femur–ACL–tibia complexes to 
obtain normal control values. The four normal knees with 
uninjured ACLs were prepared, tested, and measured in the 
same way as the experimental specimens. The specimens 
were kept moist throughout the specimen preparation and 
testing with physiologic saline solution.
Cell Proliferation Assay
To assess the proliferation ability of the cells in each 
group, cells were plated at a density of 5 ´  103 cells per 
well in 96-well plates and cultured in Dulbecco’s modified 
Eagle’s medium (Sigma) supplemented with 10% fetal 
bovine serum (Sigma). A media blank (no cells) was also 
run in parallel as a control. The plate was incubated at 37°C 
in an atmosphere of 5% CO2 for 4 days. After cultivation, 
20 μl of cell titer 96 Aqueous One Solution (Pomega, 
Madison, WI) was added to each well, and the plates 
were then incubated at 37°C in an atmosphere of 5% 
CO2 for 3 h to allow the development of color to occur. 
Absorbance was measured at 490 nm with Infinite 
200 NanoQuant and i-control microplate reader soft-
ware (TECAN, Durham, NC).
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Enzyme-Linked Immunosorbent Assay (ELISA) to Detect 
Vascular Endothelial Growth Factor (VEGF) Secretion
We determined the amount of VEGF secreted into the 
supernatant by the ACL-derived CD34+ cells, nonsorted 
cells, and CD34- cells in vitro by first incubating 1 ´  105 
of each cell type in collagen coated six-well dish for 
48 h and then measuring the amount of VEGF that was 
secreted by ELISA (R&D Systems, Minneapolis, MN), 
as previously described (30).
Statistical Analysis
All values are expressed as means ± standard errors. 
The data were compared by ANOVA test followed by the 
Tukey’s test. A probability value p < 0.05 was considered 
to denote statistical significance.
RESULTS
Efficient Incorporation of the Transplanted Cells 
To track the transplanted cells following intracapsular 
injection, immunostaining of the ACL complex for HNA 
was performed 1 week postinjection to quantify the number 
of transplanted human cells at the interface zone between 
the grafted tendon and bone, which is shown in Figure 1A 
stained with H&E. HNA immunostaining demonstrated an 
abundant recruitment of the transplanted cells to the bone 
tunnel site, especially in the CD34+ group (Fig. 1B–E). The 
number of stained human cells at the bone tunnel was signif-
icantly higher in the CD34+ group compared with the other 
groups, as well as in the NS or CD34- groups compared 
with the PBS group (CD34+, 247.3 ± 37.1; NS, 119.3 ± 17.2; 
CD34-, 68.3 ± 15.9; PBS, 0.0 ± 0.0/mm2, respectively; 
p < 0.01 for CD34+ vs. CD34- or PBS group, for NS vs. PBS 
group and for CD34- vs. PBS group, p < 0.05 for CD34+ vs. 
NS group) (Fig. 1F). These morphological findings indi-
cate that ACL-derived CD34+ cells are superior to the other 
cell groups in terms of efficiency of transplanted cell incor-
poration into the bone tunnel after intracapsular injection. 
Note that few transplanted cells were found within other 
parts of the capsule (data not shown).
Histological Evidence of Bone–Tendon Healing
Histological evaluation was performed with Masson’s 
trichrome staining to assess tendon–bone healing at 2 weeks 
postinjection. The tendon–bone interface tissue around the 
grafted tendon was observed to be composed of cellular and 
vascular fibrous tissue (Fig. 2A–D). The entire visible tendon–
bone interface areas and collagen fibers in the interface were 
measured by Scion Image analysis software. Quantification 
analysis demonstrated the total collagen fiber area was sig-
nificantly greater in the CD34+ group than the CD34- or PBS 
groups (CD34+, 66.3 ± 6.0; NS, 54.8 ± 8.1; CD34-, 43.0 ± 7.7; 
Figure 1. (A) Hematoxylin and eosin (H&E) staining with immunostaining for human nuclear antigen (HNA) (red square) showed 
the locations of the assessed areas. (B–E) The immunostaining for HNA (red) at week 1 demonstrated abundant recruitment of trans-
planted cells at the bone tunnel in the CD34+ (B) and nonsorted (NS) group (C), not in the CD34- (D) or PBS group (E). Arrow, HNA+ 
cell. Bar: 50 mm. (F) The number of transplanted cells at the bone tunnel was significantly higher in the CD34+ group compared with 
the other groups, as well as in the NS group better than the CD34- or PBS group. **p < 0.01; *p < 0.05 (n = 4 in each group). 
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PBS, 37.3% ± 7.4%, respectively; p < 0.05 for CD34+ vs. 
CD34- or PBS group). To histologically assess the healing 
of the bone–ligament junction, immunofluorescent stain-
ing for Col2 was performed using tissue samples obtained 
2 weeks posttransplantation (Fig. 2F–I). Quantification of 
the Col2-positive stained cells demonstrated that the number 
of Col2-positive cells was found to be significantly higher in 
the CD34+ group when compared to the other groups. Also, 
the number of Col2-positive cells was significantly higher 
in the NS group when compared to the CD34- and PBS 
groups (CD34+, 56.6 ± 9.0; NS, 27.4 ± 8.1; CD34-, 9.2 ± 1.3; 
PBS, 6.1 ± 0.9/mm2, respectively; p < 0.01 for CD34+ vs. 
CD34- and PBS group; p < 0.05 for CD34+ vs. NS group; 
p < 0.01 for NS vs. PBS group; p < 0.05 for NS vs. CD34- 
group) (Fig. 2J).These results indicate that ACL-derived 
CD34+ cells contribute to rapid tendon osteointegration in 
the early period after ACL reconstruction.
Enhancement of Intrinsic Vascularization  
and Osteogenesis
Enhanced angiogenesis and osteogenesis imparted by the 
transplanted cells on the recipients’ cells was confirmed by 
immunostaining for rat-specific markers.  This enhancement 
is believed to be a paracrine induced effect imparted by the 
implanted donor cells. Vascular staining with isolectin B4, a 
rat-specific marker for ECs, using tissue samples collected 2 
weeks after ACL reconstruction, demonstrated an enhance-
ment in intrinsic neovascularization around the bone tunnel 
in animals treated with ACL-derived CD34+ and NS cells 
(Fig. 3A–D). Capillary density determined by analyzing 
isolectin B4 was significantly greater in the CD34+ group 
compared with the other groups, and the NS group was sig-
nificantly greater compared with the CD34- and PBS groups 
(CD34+, 316.5 ± 37.6; NS, 196.5 ± 28.6; CD34-, 113.0 ± 17.9; 
PBS, 105.8 ± 13.2/mm2, respectively; p < 0.01 for CD34+ 
vs. CD34- or PBS group, p < 0.05 for CD34+ vs. NS group 
and for NS vs. CD34- or PBS group) (Fig. 3E). OB stain-
ing using rat OC antigen demonstrated an enhancement of 
intrinsic osteogenesis at the perigraft sites in animals treated 
with ACL-derived CD34+ and NS cells (Fig. 3F–I). OB den-
sity, as determined with a rat OC antibody, was significantly 
greater in the CD34+ group compared with the other groups, 
and the NS group was significantly greater compared with 
the CD34- and PBS groups (CD34+, 147.0 ± 15.2; NS, 
71.5 ± 17.5; CD34-, 43.8 ± 15.2; PBS group, 21.8 ± 9.8/mm2, 
respectively; p < 0.01 for CD34+ vs. CD34- or PBS group, 
p < 0.05 for CD34+ vs. NS group and for NS vs. PBS group) 
(Fig. 3J). These results indicate that ACL-derived CD34+ 
and NS cells enhance both intrinsic angiogenesis and osteo-
genesis at the tendon–bone interface zone.
Human Cell-Derived Vasculogenesis and Osteogenesis 
Immunohistochemical staining for hEC and hOB 
markers was performed using the tissue samples har-
vested at week 2. Differentiated human ECs were identi-
fied as hCD31-positive cells at the vascular sites stained 
with isolection B4 in the CD34+, NS, and CD34- groups 
(Fig. 4A–E). The number of human-derived ECs was signif-
icantly greater in the CD34+ group compared with the other 
groups, and the NS group was significantly greater com-
pared with the CD34- and PBS groups (CD34+, 84.8 ± 10.3; 
NS, 36.0 ± 11.1; CD34-, 6.8 ± 3.3; PBS, 0.0 ± 0.0/mm2, 
respectively; p < 0.01 for CD34+ vs. the other groups and 
for NS vs. PBS group, p < 0.05 for NS vs. CD34- group) 
(Fig. 4F). To further verify this phenomenon, RT-PCR anal-
ysis of tissue RNA isolated from the peribone tunnel site 
for human-specific EC markers (hVE-cad and hCD31) was 
performed. The expressions of hVE-cad and hCD31 were 
detected in the CD34+ and NS groups (Fig. 4G). 
Differentiated hOBs were identified as double posi-
tive cells with HNA and hOC in the area of newly formed 
bone in the CD34+, NS, and CD34- groups (Fig. 4H–L). 
The number of human-derived OB cells was significantly 
greater in the CD34+ group compared with the other groups, 
and the NS group was significantly greater compared to the 
CD34- and PBS groups (CD34+, 43.5 ± 11.0; NS, 21.0 ± 7.5; 
CD34-, 2.3 ± 1.4; PBS group, 0.0 ± 0.0/mm2, respectively; 
p < 0.01 for CD34+ vs. CD34- or PBS group and for NS 
vs. CD34- or PBS group, p < 0.05 for CD34+ vs. NS group) 
(Fig. 4M). RT-PCR analysis also demonstrated expression of 
the human-specific bone-related markers (hOC and hCol1) 
following human CD34+ cell transplantation (Fig. 4N). These 
results indicate that intracapsslar transplanted ACL-derived 
CD34+ cells can effectively differentiate into both EC and 
OB lineages at the tendon–bone interface zone in vivo.
Bone Volume Evaluation by Micro-CT
The perigraft bone volume was evaluated with micro-CT. 
A transient perigraft bone mass decrease was observed in 
all groups at week 2. There was no significant difference 
Figure 2. (A–D) Histological evaluations with Masson’s trichrome staining. The tendon–bone interface tissue around the grafted ten-
don was observed to be composed of cellular and vascular fibrous tissue. The total collagen fiber area was significantly greater in the 
CD34+ group (A) than the CD34- (C) or PBS groups. (D) Scale bar: 50 mm. B, bone; IF, interface zone; T, tendon. (E) Quantification 
analysis demonstrated the total collagen fiber area was significantly greater in the CD34+ group than the CD34- or PBS group at week 
2. **p < 0.01; *p < 0.05 (n = 6 in each group). (F–I) Immunofluorescent staining for type II collagen (Col2) on tissue samples obtained 
2 weeks posttransplantation demonstrated better regeneration between the graft and the bones in the CD34+ and NS groups when com-
pared with the other groups. (J) Quantification of the Col2-positive stained cells demonstrated that the number of Col2-positive cells 
was found to be significantly higher in the CD34+ group when compared to the other groups and that the number of Col2-positive cells 
was significantly higher in the NS group when compared to the CD34- and PBS groups. **p < 0.01; *p < 0.05 (n = 6 in each group).
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Figure 3. (A–D) Enhancement of neovascularization and osteogenesis by recipient cells following anterior cruciate (ligament) 
ACL-derived cell transplantation. Representative vascular staining with isolectin B4 using tissue samples collected at week 2. Scale 
bar: 50 mm. (E) Neovascularization assessed by capillary density at week 2 was significantly greater in the CD34+ group compared 
with the other groups, as well as in the NS group better than the CD34- or PBS group **p < 0.01; *p < 0.05 (n = 6 in each group). 
(F–I) Representative osteoblast (OB) staining with rat osteocalcin (bright spots) at week 2. Scale bar: 50 mm. (J) Osteogenesis assessed 
by OB density at week 2 was significantly greater in the CD34+ group compared with the other groups, as well as in the NS group 
compared with the PBS group. **p < 0.01; *p < 0.05 (n = 6 in each group). 
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Figure 4. (A–E) Perigraft site vasculogenesis derived from ACL-derived cells. Representative double immunostaining for hCD31 
(red) and isolectin B4 (green) using tissue samples at week 2. Scale bar: 50 mm. Differentiated human endothelial cells (ECs) iden-
tified as hCD31-positive cells (red) were observed in the CD34+ (A, E) and NS (B) but not in the CD34- and PBS groups (C, D). 
Arrow, double-positive cells. E is higher magnification image of dotted box in A. (F) The number of human-derived ECs was signifi-
cantly greater in the CD34+ group compared with the other groups, as well as in the NS group greater than the CD34- or PBS group. 
**p < 0.01; *p < 0.05 (n = 6 in each group). (G) The mRNA expressions of human vascular endothelial cadherin (hVE-cad) and hCD31 
were detected from tissue RNA isolated from the perigraft site in the CD34+ and NS groups. Posi, positive control from human umbili-
cal vein endothelial cells (HUVECs); Nega, negative control with no RNA. (H–L) Representative immunostaining for HNA (red) and 
hOC (green) using samples collected at week 2. Scale bar: 50 mm. Differentiated human OBs identified as hOC-positive cells (green) 
were observed in the CD34+ (H, L), NS (I), and CD34- group (J) but not in the PBS group (K). L is higher magnification image of dot-
ted box in H. (M) The number of human-derived OB was significantly greater in the CD34+ group compared with the other groups, as 
well as in the NS group greater than the CD34- or PBS group. **p < 0.01; *p < 0.05 (n = 6 in each group). (N) The mRNA expression 
of hOsteocalcin (OC) and type I collagen (hCOL1) were detected from RNA isolated from tissues from the peribone tunnel site in the 
CD34+ and NS groups. Posi, positive control from fetal bone; Nega, negative control with no RNA.
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among any of the groups in BV/TV at weeks 0 and 2 
(week 0: CD34+, 0.483 ± 0.004; NS, 0.497 ± 0.023; CD34-, 
0.524 ± 0.022; PBS, 0.514 ± 0.027, respectively, p = NS; 
week 2: CD34+, 0.479 ± 0.022; NS, 0.488 ± 0.063; CD34-, 
0.483 ± 0.049; PBS, 0.500 ± 0.059, respectively, p = NS), 
while the BV/TV at week 4 was significantly higher in the 
CD34+ group compared with the CD34- and PBS groups 
(week 4: CD34+, 0.651 ± 0.038; NS, 0.589 ± 0.049; CD34-, 
0.476 ± 0.069; PBS, 0.502 ± 0.043, respectively, p < 0.05 for 
CD34+ vs. CD34- or PBS group) (Fig. 5A). These results 
indicate that the ACL-derived CD34+ cells contribute to 
perigraft bone mass increase after ACL reconstruction.
Biomechanical Testing
Functional recovery of ACL reconstruction in each group 
was evaluated by failure load of biomechanical tensile test at 
week 8 postinjection. In all samples, the grafts were pulled 
out from the femoral or tibial bone tunnel subjected to failure 
load tests. Failure load of tensile test demonstrated that bio-
mechanical strength was significantly higher in the CD34+ 
cell group compared with the other groups and the NS group 
was significantly higher compared with the CD34- and PBS 
groups; however, the uninjured control group showed a signif-
icantly greater result when compared with all the experimen-
tal groups (CD34+, 19.48 ± 0.85; NS, 14.66 ± 2.17; CD34-, 
Figure 5. (A) The perigraft bone volume was evaluated with micro-CT. Transient perigraft bone 
mass decrease was observed in all groups at week 2. There was no significant difference among all 
groups in the bone volume/tissue volume (BV/TV) at weeks 0 and 2, while the BV/TV at week 4 
was significantly higher in the CD34+ group compared with the CD34- or PBS group. *p < 0.05 (n = 6 
in each group). (B) Biomechanical recovery of ligament injury in animals receiving ACL-derived 
cell transplantation. Failure load of tensile test demonstrated that biomechanical strength was sig-
nificantly higher in the CD34+ cell group compared with the other groups and the NS group was 
significantly higher compared with the CD34- and PBS groups; however, the uninjured control group 
showed a significantly greater result when compared with all the experimental groups. **p < 0.01; 
*p < 0.05; +p < 0.01 for all experimental groups (n = 4 in each group).
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7.64 ± 1.53; PBS, 7.67 ± 0.96; uninjured control, 27.54 ± 1.14, 
respectively, p < 0.01 for CD34+ vs. CD34- or PBS group and 
uninjured verses all experimental groups, p < 0.05 for CD34+ 
vs. NS group and NS vs. CD34- or PBS group) (Fig. 5B). 
These results indicate that the transplanted autologous graft 
in the immunodeficient rats were biomechanically healed 
with the administration of ACL-derived CD34+ cells.
In Vitro Cell Proliferation Assay
To investigate the proliferation capabilities of each of 
the cell groups, we performed a cell proliferation assay 
with Cell Titer 96 Aqueous One Solution. The absorbance 
ratio of each of the cell groups to a control group was 
calculated to normalize the effect of the media. The cell 
proliferation assay showed that the CD34+ group had a 
significantly greater proliferation ability than the other 
two groups. The NS cell group also demonstrated a sig-
nificantly greater proliferation ability than the CD34- 
group (CD34+, 2.13 ± 0.60; NS, 1.63 ± 0.84; CD34-, 
1.27 ± 0.49; no cell, 0.27 ± 0.04, respectively, p < 0.01 for 
CD34+ vs. NS, CD34- or PBS group and NS vs. CD34- or 
PBS group) (Fig. 6A).
Figure 6. (A) The cell proliferation assay showed that the CD34+ group had a significantly greater 
ability for proliferation than the other two groups. The NS was also significantly greater than the 
CD34- group. **p < 0.01 (n = 6 in each group). (B) Enzyme-linked immunosorbent assay (ELISA) 
for vascular endothelial growth factor (VEGF) revealed that VEGF secretion in the CD34+ group was 
significantly increased compared to the other two groups. The NS was also significantly greater than 
the CD34- group. **p < 0.01 (n = 6 in each group).
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VEGF Secretion Levels
VEGF levels were measured in the medium of the cell 
cultures using ELISA, which showed that VEGF levels 
in the CD34+ group was significantly higher compared to 
the other two groups. The NS cell group was also signifi-
cantly greater than the CD34- group (CD34+, 63.5 ± 4.9; 
NS, 31.3 ± 3.4; CD34-, 6.7 ± 0.5, respectively, p < 0.01 for 
CD34+ vs. NS or CD34- group and NS vs. PBS group) 
(Fig. 6B).
DISCUSSION
This is the first report that we are aware that utilize 
ACL-derived cells to aid in the healing of ACL recon-
struction. The study demonstrated that these certain 
populations of these ACL-derived cells can differentiate 
into ECs and OBs when injected into the joint capsules of 
reconstructed ACLs. The objective of this study was to 
develop a new strategy to accelerate the healing between 
graft tendon and bone after ACL reconstruction. 
Initially, we examined the efficiency of incorporation 
into the perigraft site after the intracapuslar injection of 
each cell group. Our immunohistochemical evaluations 
showed that the greatest number of transplanted cells that 
migrated into the perigraft site were ACL-derived CD34+ 
cells (Fig. 1). Stem cells, like bone marrow mesenchymal 
stem cells (BM-MSC) and synovial stem cells, have been 
reported to migrate to injured tissues after intracapuslar 
injection (1,13,17). This result could be explained by the 
fact that the CD34+ cell marker is known as a hematopoi-
etic stem/endothelial progenitor cell marker (2) and the 
ACL-derived cells isolated on the basis of CD34 showed 
that the CD34+ cells demonstrated the best regenerative 
capacity among the other cell groups isolated (CD34- and 
unsorted cells) cells.
At week 2 after ACL reconstruction, the application 
of ACL-derived CD34+ and NS cells had the poten-
tial to accelerate the early remodeling of tendon–bone 
healing histologically by forming a greater numbers of 
collagen fibers connecting the bone to the tendon and 
Col2-positive cells (chondrocytes) (Fig. 2). Tendon–bone 
healing has been reported to be enhanced with more per-
pendicular collagen fibers being deposited and the pro-
liferation of cartilage-like tissue within the bone tunnels 
(29). Moreover, we investigated the therapeutic ability of 
the ACL-derived cells for their angiogenesis and osteo-
genesis potentials. The immunohistological results in this 
study indicated that the ACL-derived CD34+ and NS cells 
could produce the intrinsic effect necessary to promote 
angiogenesis and osteogenesis (Fig. 3). These cells were 
also shown to be capable of differentiating into ECs and 
OBs at the perigraft sites (Fig. 4). In a previous study of 
ours, we have already shown that ACL-derived stem cells 
isolated from the site of ACL rupture have the potential 
for multilineage differentiation including osteogenic, 
chondrogenic, adipogenic, and endothelial differentiation 
in vitro (26), of which, osteogenic and endothelial differ-
entiations are especially important for good quality bone-
tendon healing (21). In fact, various cytokines and growth 
factors including VEGF (41), platelet-derived growth 
factor (PDGF) (22), fibroblast growth factor 2 (FGF2) 
(21), granulocyte colony-stimulating factor (G-CSF) 
(33), transforming growth factor-b (TGF-b) (40), bone 
morphogenetic protein 2 (BMP 2) (25), and BMP 7 (27) 
have recently received attention for their therapeutic 
potential to accelerate osteogenesis and/or angiogenesis 
for improving tendon–bone healing. Moreover, some 
stem/progenitor cells including BM-MSC (23,29,34) and 
s yno vial stem cells (15) have also received  attention for 
their potential to accelerate osteogenesis and/or angio-
genesis to help improve tendon–bone healing.
Furthermore, we evaluated perigraft bone volume 
using a micro-CT to reveal bone healing at the perigraft 
site. The perigraft bone mass was observed to decreased 
in all groups at week 2 (Fig. 5), which could be caused 
by graft fixation weakness or the activity immediately 
after surgery. That is, both ends of the grafted tendon were 
secured to the surrounding periosteum at the extra-articu-
lar tunnel exit sites at the distal femur and proximal tibia 
using 4-0 Ethibond sutures in this animal model (20), and 
after surgery the animals were allowed to move freely 
within the cage without fixating the reconstructed leg. 
At 4 weeks after ACL reconstruction, micro-CT evalu-
ation showed that the ACL-derived CD34+ cells contrib-
uted to an increase in bone mass at the perigraft sites. 
It has previously been reported that the healing quality 
of tendon–bone attachment is influenced by perigraft 
bone mass (11) and that tendon–bone attachment strength 
was directly related to perigraft bone mass after ACL 
reconstruction (38). Hence, our results obtained from the 
micro-CT appeared to highly correlate with our biome-
chanical results. 
Finally, the functional healing between bone and graft 
after ACL reconstruction had been assessed by failure 
load of biomechanical tensile test at week 8 postrecon-
struction. Failure loads obtained in both the CD34+ and 
NS groups were significantly higher compared with the 
CD34- and PBS groups (Fig. 5); however, in comparison 
with uninjured knees, only the CD34+ group exhibited 
almost the same strength as the uninjured knees in failure 
load test. These results were supported by the histological 
findings which demonstrated better healing in the CD34+ 
cell group when compared to the other groups. The ACL 
reconstructions in the immunodeficient rats were not only 
enhanced biologically with the administration of ACL-
derived CD34+ cells but also biomechanically. Previous 
studies have also reported that the maximum pullout load 
progressively increases as collagen fibers continue to grow 
and as the interface healing matures histologically (32).
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In an attempt to clarify why the ACL-derived CD34+ 
cells had a superior influence on the healing of the ACL 
reconstructions, we performed in vitro assays to deter-
mine the cell’s proliferation capacities and levels of 
VEGF secretion (Fig. 6). Both assays demonstrated, at 
least in part, potential mechanisms behind the benefi-
cial effects imparted by the ACL-derived CD34+ cells. 
It has previously been reported that population doubling 
(PD) times exhibited by the ACL-derived CD34+ cells 
were significantly higher than the PD times exhibited 
by ACL-derived CD34- cells (26). In the current study, 
we revealed that the CD34+ cell group also had sig-
nificantly greater capacities for cell proliferation when 
compared with the non-sorted and CD34- cells. The cell 
surface marker CD34 is considered a hematopoietic stem/
endothelial progenitor cell marker (2), and CD34+ cells 
from the bone marrow and peripheral blood have been 
reported to secret greater amounts of VEGF than CD34- 
cells (24). We also confirmed that ACL-derived CD34+ 
cells could secret higher levels of VEGF than the non-
sorted and CD34- cells in this study.
On the whole, the biological evaluations (Figs. 1–4) 
demonstrated that both the ACL-derived CD34+ and NS 
cells had the potential to promote tendon–bone heal-
ing, while the micro-CT and biomechanical evaluations 
(Fig. 5) demonstrated that the only the ACL-derived 
CD34+ cells had the ability to create a quality tendon–
bone attachment. Furthermore, the in vitro studies 
indicated that the ACL-derived CD34+ cells showed 
increased cell proliferation capabilities and increased 
VEGF secretion levels (Fig. 6). We therefore came to 
the conclusion that only the ACL-derived CD34+ cells 
were highly effective for aiding the rapid recovery of 
ACL reconstructions.
The CD34+ cells isolated from bone marrow and 
peripheral blood have already been used in a clinical set-
ting for the repair of various damaged tissues including 
lower limb ischemia, myocardial infarction, and nonunion 
fracture, because these cell populations have been recog-
nized to be a rich population of hematopoietic/endothelial 
progenitor cells (2). As our previous study indicated, the 
ACL-derived CD34+ cells used in this study were consid-
ered to be derived from the vascularized area of the ACL 
(26), and therefore, the origin of the ACL-derived CD34+ 
cells may be the same as the bone marrow/peripheral 
blood-derived CD34+ cells.
Several limitations should be noted in this study. Firstly, 
although we have already clarified the multidifferentia-
tion capacity of ACL-derived cells into ECs and OBs, we 
have not demonstrated whether the ACL-derived cells 
might have the potential to differentiate into fibroblasts to 
directly contribute to the graft tendon healing. Secondly, 
the rat model used in the present study is very small and 
the tendon–bone healing process occurs at a faster rate in 
rats than in humans. We need further studies to test the 
effectiveness of this application in a large-animal model 
to confirm its clinical feasibility. If the treatment of ACL-
derived cells produces a clinical effect, it could improve 
rehabilitation and produce a better outcome for ligament 
reconstructions in general.
In conclusion, our results demonstrated that ACL-
derived CD34+ cells isolated from the site of ACL rupture 
exhibited stem cell characteristics and may contribute to 
tendon–bone healing in ACL reconstruction. The present 
findings provide important clinical insight for regenerative 
medicine aimed at enhancing tendon–bone healing in ACL 
reconstruction, and the methods used in the current study 
could one day be translated into a clinically reasonable 
treatment regime to enhance ACL reconstruction repair.  
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